Betta Pharmaceuticals Co Ltd Total Liabilities
Betta Pharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Betta Pharmaceuticals Co Ltd (300558) has total liabilities worth CN¥3.83 Billion CNY (≈ $559.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300558 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Betta Pharmaceuticals Co Ltd (2011–2025)
Total liabilities of Betta Pharmaceuticals Co Ltd from 2011 to 2025. This chart illustrates how Betta Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 300558 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Betta Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Betta Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Patrick Industries Inc
NASDAQ:PATK
|
USA | $2.08 Billion |
|
Joyoung Co Ltd
SHE:002242
|
China | CN¥3.57 Billion |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
India | Rs199.80 Billion |
|
Shenzhen Chengxin Lithium Group Co Ltd
SHE:002240
|
China | CN¥13.13 Billion |
|
Guizhou Chanhen Chemical Corp
SHE:002895
|
China | CN¥4.65 Billion |
|
Embotelladora Andina S.A
SN:ANDINA-B
|
Chile | CL$2.13 Trillion |
|
Amot Investments Ltd
TA:AMOT
|
Israel | ILA12.18 Billion |
|
Four Corners Property Trust Inc
NYSE:FCPT
|
USA | $1.37 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Betta Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Betta Pharmaceuticals Co Ltd's balance sheet.
Liquidity & Leverage Metrics
Betta Pharmaceuticals Co Ltd Total Liabilities Ratios Explained
Betta Pharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Betta Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below shows the annual total liabilities of Betta Pharmaceuticals Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.90 Billion ≈ $570.39 Million |
+6.05% |
| 2024-12-31 | CN¥3.68 Billion ≈ $537.85 Million |
-3.16% |
| 2023-12-31 | CN¥3.80 Billion ≈ $555.39 Million |
+28.55% |
| 2022-12-31 | CN¥2.95 Billion ≈ $432.04 Million |
+86.20% |
| 2021-12-31 | CN¥1.59 Billion ≈ $232.03 Million |
+44.66% |
| 2020-12-31 | CN¥1.10 Billion ≈ $160.40 Million |
-34.13% |
| 2019-12-31 | CN¥1.66 Billion ≈ $243.51 Million |
+31.46% |
| 2018-12-31 | CN¥1.27 Billion ≈ $185.24 Million |
+79.18% |
| 2017-12-31 | CN¥706.48 Million ≈ $103.38 Million |
+196.51% |
| 2016-12-31 | CN¥238.27 Million ≈ $34.87 Million |
-5.86% |
| 2015-12-31 | CN¥253.09 Million ≈ $37.04 Million |
+111.09% |
| 2014-12-31 | CN¥119.90 Million ≈ $17.54 Million |
+30.74% |
| 2013-12-31 | CN¥91.71 Million ≈ $13.42 Million |
+3.69% |
| 2012-12-31 | CN¥88.44 Million ≈ $12.94 Million |
-45.68% |
| 2011-12-31 | CN¥162.83 Million ≈ $23.83 Million |
-- |
About Betta Pharmaceuticals Co Ltd
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma… Read more